Introduction

Lentiviral vectors (LVs) have become one of the most widely used vectors in basic biological research, functional genomics, and gene therapy. It is a single-stranded positive-sense RNA virus belonging to the retrovirus family. The packaging capacity of this viral vector ranges from 8-9 kb. The main advantages of this viral vector are sustained gene transfer in the transduced tissue and preferential integration in the 3' region of the host gene. Currently, major developments in lentiviral gene therapy are focused on diseases associated with RPE dysfunction, including age-related macular degeneration degeneration and some forms of hereditary retinal dystrophy (IRD) due to lentiviruses have been shown to have limited tropism for RPE.

Fig. 1. Diseases currently targeted by LV. (Arsenijevic Y, et al., 2022)

Service Overview

Ace Therapeutics is a comprehensive ophthalmology preclinical CRO. Our talented scientists have extensive experience in the field of gene therapy. We can customize exclusive lentiviral gene therapy product development services according to your research project.

Based on years of hard work and exploration in the field of gene therapy, Ace Therapeutics currently provides a large number of lentiviral vector services for the treatment of eye diseases. Our custom solutions cover virtually every step of your project, including but not limited to:

• Lentiviral vector optimization service.
• Lentiviral vector design for regulatory integration and expression.
• Safety determination of lentiviral vector service.
• Lentiviral vector titration service.
• Advanced lentiviral vector development for ocular gene therapy.

Why Choose Development of Lentivirus-Based Ocular Gene Therapy Products?

Lentiviral vectors have been investigated as potential tools for ocular gene delivery. These vectors offer the potential advantages of limited immune response and gene delivery into the host cell genome. Ace Therapeutics has extensive experience in the design, biosafety, and development of lentiviral vectors for transgene expression into target cells. Compared with other vectors, gene therapy products based on lentiviral vectors are more safe and effective.

Our Areas of Expertise

• Retinal disease.
• Age-related macular degeneration.
• Hereditary eye disease.
• Glaucoma.
• Corneal disease.
• Optic nerve disease.

Ace Therapeutics is constantly working on improving the lentiviral vector system to generate safer, higher-titer vectors to meet your eye disease gene therapy research requirements.If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

Reference

1. Arsenijevic Y, Berger A, Udry F, et al. Lentiviral Vectors for Ocular Gene Therapy. Pharmaceutics. 2022;14(8):1605.

• AAV Vector Development Services for Ocular Nucleic Acid-Based Therapy
• Non-Viral Vector Development Services for Ocular Nucleic Acid-Based Therapy
• Recombinant Adeno-Associated Virus Vector Development Services for Ocular Nucleic Acid-Based Therapy
• Delivery System Development Services for Ocular Nucleic Acid-Based Therapy
• CRISPR/Cas9 Gene Editing Services for Ocular Nucleic Acid-Based Therapy
• Safety and Toxicology Assessment Services for Ocular Nucleic Acid-Based Therapy
• Potency Testing Services for Ocular Nucleic Acid-Based Therapy

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit